Baxter International

Baxter International is an American multinational healthcare company whose products are used in hospitals, outpatient facilities, surgical settings, pharmacies, and home-care environments. Its historic portfolio has centered on intravenous therapy, infusion systems, dialysis, injectable pharmaceuticals, surgical products, and equipment used to monitor or support patients with acute and chronic conditions. The company is headquartered in Deerfield, Illinois, and operates internationally through manufacturing, research, distribution, and commercial organizations. Donald Baxter founded the company in 1931 as a manufacturer and distributor of intravenous therapy solutions. The business expanded beyond its original Los Angeles base after opening a plant in Glenview, Illinois, in 1933. Ralph Falk acquired Baxter's interest in 1935 and established a more formal research-and-development capability. Early technical milestones included a vacuum blood-collection container introduced in 1939, which extended the practical storage life of collected blood, and an artificial-kidney system introduced in the 1950s. These developments helped define Baxter's long-term identity as a supplier of products supporting fluid management, blood treatment, renal replacement, and hospital care. Baxter internationalized its operations during the 1950s and subsequently broadened its business through acquisitions and internal development. The 1985 merger with American Hospital Supply created one of the largest US medical-supply companies of the period and supported a strategy of offering hospitals a broad range of products. During the 1980s and 1990s, Baxter also participated in blood products, vaccines, pharmaceuticals, home infusion, and other healthcare services. Some activities were later divested or separated, including Caremark International, which was spun off in 1992, and the biopharmaceutical business Baxalta, which became an independent public company in 2015. In the 2010s and early 2020s, Baxter emphasized medical products, infusion technologies, pharmaceuticals, surgical products, connected-care systems, and patient-monitoring or hospital-support technologies. Acquisitions such as Gambro, Baxa, Claris Injectables, Seprafilm, and Hillrom expanded its renal, medication-management, injectable, surgical, and connected-care capabilities. Baxter also announced the sale of its biopharma solutions business in 2023 and agreed in 2024 to divest its kidney-care business, Vantive, to Carlyle. These transactions represented a continuing effort to focus the portfolio around hospital products, therapies, and technology-enabled care. Baxter's business has also been affected by product-safety, manufacturing, regulatory, and legal controversies. Historical issues have included contaminated blood products, the Althane dialysis-related deaths, the 2008 heparin contamination crisis, infusion-pump recalls, and allegations connected with anti-boycott and home-infusion practices. In 2024, flooding from Hurricane Helene disrupted production at the company's Marion, North Carolina, facility, a major US source of intravenous fluids. The interruption contributed to national IV-fluid shortages and led hospitals to conserve supplies while production was gradually restored. Baxter remains an active listed healthcare company, with its brand associated particularly with infusion, hospital, surgical, pharmaceutical, and renal-care products.

Baxter International began in 1931 when physician Donald Baxter established a Los Angeles business to manufacture and distribute intravenous therapy solutions. The company moved toward a broader manufacturing base by opening a Glenview, Illinois, plant in 1933. Ralph Falk acquired Baxter's interest in 1935 and strengthened the company’s research and development activities. In 1939, Baxter developed a vacuum-type blood-collection container that helped preserve blood for substantially longer periods than earlier systems. The company expanded outside the United States in 1954 with an office in Belgium. In 1956, it introduced a functioning artificial kidney, establishing an important connection between the Baxter name and renal replacement therapy. Baxter became a Fortune 500 company in 1971 and built a major plant in Ashdod, Israel, that same year. The Israeli operation later contributed to the company’s appearance on the Arab League boycott list during the early 1980s. Baxter pursued diversification through acquisitions during the 1980s and 1990s. It acquired Medcom in 1982 and merged with American Hospital Supply Corporation in 1985. The American Hospital Supply transaction significantly expanded Baxter's hospital-supply distribution and helped create a broad medical-products platform. Baxter also entered or expanded in vaccines, blood products, pharmaceuticals, and home infusion. Caremark International, its home-infusion subsidiary, was accused of paying physicians to refer patients to its services. Caremark was spun off in 1992 and later paid a substantial federal penalty in connection with a mail-fraud and kickback case. The company faced further controversy involving its international business and blood products. In 1993, Baxter pleaded guilty to a felony related to US anti-boycott law. In the mid-1990s, it reached a major settlement involving haemophiliac patients infected with HIV through contaminated clotting concentrates. Poor performance and the aftermath of an unsuccessful merger contributed to shareholder pressure on Vernon Loucks, who left the chief executive role after a long tenure during which Baxter's sales and workforce grew considerably. Baxter continued developing vaccines and hospital therapies in the 2000s. In 2001, the Althane dialysis disaster was associated with more than 50 sudden deaths among kidney-failure patients in several countries, leading to intense scrutiny of the product range and its manufacturing. In 2008, contaminated heparin supplied through a Chinese subcontracting chain was linked by US authorities to deaths and severe allergic reactions. Baxter recalled affected products, suspended production, and participated in investigations into the raw material. The company announced in 2009 that it had completed the first commercial H1N1 influenza vaccine using cell-based technology. It also faced product-liability and regulatory actions, including a 2010 order to recall Colleague infusion pumps after numerous recalls and reported deaths. Baxter acquired Baxa in 2011, sold its US generic injectables business to Hikma Pharmaceuticals that year, received European approval for its Gambro acquisition in 2013, and completed the Gambro transaction in 2014. A major strategic reorganization followed. Baxter announced in 2014 that its biopharmaceutical activities would be separated from its medical-products activities. Baxalta became an independent company in 2015, while Baxter retained the medical-products identity. Baxter also exited the commercial vaccines business, transferring its portfolio to Pfizer. It subsequently acquired Claris Injectables in 2016 and Seprafilm from Sanofi in 2019. The Hillrom acquisition, announced in 2021 and completed later that year, expanded Baxter into connected care, patient support, monitoring, and hospital technologies. In 2023, Baxter agreed to sell its biopharma solutions business to private-equity buyers. In 2024, it agreed to divest Vantive, its kidney-care unit, to Carlyle. Also in 2024, Hurricane Helene flooded Baxter's Marion, North Carolina, facility, disrupting a major portion of US IV-fluid production and causing nationwide supply pressures. Partial manufacturing resumed later that year, but hospitals continued conservation measures during the recovery. Baxter's present portfolio therefore reflects both its historic strengths in infusion and renal care and a broader emphasis on surgical, pharmaceutical, hospital-technology, and connected-care products.

1. 2024North Carolina IV-fluid facility disrupted

   Hurricane Helene flooding disrupted production at Baxter's Marion facility and contributed to US IV-fluid shortages.

   Source
2. 2021Hillrom acquisition completed

   Baxter completed its acquisition of Hillrom, adding connected-care and hospital-technology capabilities.

   Source
3. 2015Baxalta becomes independent

   The biopharmaceutical business began trading independently as Baxalta, while Baxter retained its medical-products operations.

   Source
4. 2014Baxalta separation announced

   Baxter announced plans to separate its biopharmaceutical operations from its medical-products company.

   Source
5. 2009Cell-based H1N1 vaccine completed

   Baxter announced completion of a commercial H1N1 vaccine made with cell-based rather than egg-based technology.

   Source
6. 2008Heparin contamination crisis

   Baxter recalled heparin products and suspended manufacturing after contaminated raw material was linked to deaths and severe allergic reactions.

   Source
7. 2001Althane dialysis disaster

   A series of patient deaths in multiple countries was associated with Althane hemodialysis equipment and prompted major scrutiny.

   Source
8. 1992Caremark spun off

   Baxter separated its home-infusion subsidiary Caremark International as an independent company.

   Source
9. 1985American Hospital Supply merger

   Baxter merged with American Hospital Supply Corporation, substantially enlarging its medical-supply platform.

   Source
10. 1956Artificial-kidney system introduced

    Baxter introduced what the historical record describes as the first functioning artificial kidney.

    Source
11. 1954First overseas office

    Baxter opened an office in Belgium as part of its international expansion.

    Source
12. 1939Vacuum blood-collection container developed

    The company developed a vacuum-type container that extended the usable storage life of collected blood.

    Source
13. 1933Glenview manufacturing plant opens

    Baxter opened a manufacturing facility in Glenview, Illinois, to serve markets closer to the US Midwest.

    Source
14. 1931Company founded

    Donald Baxter founded the company in Los Angeles to manufacture and distribute intravenous therapy solutions.

    Source

A global healthcare-products supplier focused on therapies and technologies that support hospital care, infusion and medication delivery, surgery, pharmaceuticals, and renal treatment.

• Intravenous solutions and infusion therapiesInfusion and hospital products1931

  Baxter's historic and widely recognized product area includes IV fluids, administration sets, containers, and technologies for delivering fluids, nutrition, and medicines. These products are used across hospitals, clinics, emergency care, and other treatment settings. The category has remained central to the company's identity and has also made Baxter strategically important to national hospital supply chains.

• Infusion pumpsInfusion technology

  Baxter develops infusion-pump systems designed to control the delivery of fluids and medications. The products support clinical workflows in hospitals and other care environments, although the company's pump portfolio has also been subject to significant regulatory scrutiny and recalls, including the Colleague pump recall in 2010.

• Renal-care and dialysis productsRenal therapy1956

  Renal products include hemodialysis equipment and supplies, peritoneal-dialysis therapies, and related treatment consumables. Baxter's involvement in artificial-kidney development and dialysis equipment dates back to the 1950s. The kidney-care business was later organized as Vantive and became the subject of a planned divestiture announced in 2024.

• Injectable pharmaceuticalsHospital pharmaceuticals

  Baxter's pharmaceutical activities include hospital injectables and differentiated medicines used in areas such as pain management, critical care, anti-infective treatment, oncology, and anesthesia. The company expanded this capability through acquisitions and partnerships, including the purchase of Claris Injectables.

• Surgical productsSurgical technologies

  The surgical portfolio includes products intended to support tissue management, hemostasis, adhesion prevention, and operating-room procedures. Seprafilm, acquired from Sanofi, is an example of a surgical product added through portfolio expansion. Baxter also describes advanced surgery as a business focused on improving surgical technique, efficiency, and outcomes.

• Hillrom care and connectivity systemsHealthcare technology2021

  The Hillrom business broadened Baxter's offering into patient beds, monitoring, virtual-care support, connected-care systems, and technologies that help hospitals coordinate clinical information and workflows. These products complement Baxter's consumables and therapies by addressing the physical and digital infrastructure of patient care.

• 2014Dollars for Doers

  Global

  The Baxter International Foundation supported employee volunteering on healthcare, environmental, and education projects by contributing to community organizations connected with employee service.

  Outcome. Employee-volunteering and community-support program.

  Source
• 2008Science@Work: Expanding Minds with Real-World Science

  United States · Chicago

  Baxter launched an education initiative supporting teacher training and student development in healthcare and biotechnology within Chicago Public Schools.

  Outcome. Community education and workforce-development program.

  Source

• 2024Agree to divest VantiveM&A

  Baxter pursued portfolio focus while addressing the distinct capital and operating needs of kidney-care activities.

  What changed. The company agreed to sell its Vantive kidney-care business to Carlyle.

  Aftermath. The planned transaction would separate Baxter's kidney-care operations from the remaining company.

  announced transaction value. $3.8 billion (2024)

  Source
• 2023Sell biopharma solutions businessM&A

  Baxter continued simplifying its portfolio and concentrating on core healthcare products and technologies.

  What changed. The company agreed to sell its biopharma solutions business to Warburg Pincus and Advent International.

  Aftermath. The divestiture reduced Baxter's exposure to contract biopharmaceutical support services.

  cash consideration. $4.25 billion (2023)

  Source
• 2021Acquire HillromM&A

  Baxter aimed to add connected-care, patient-support, and hospital-technology capabilities to its therapies and products portfolio.

  What changed. Baxter agreed to acquire Hillrom and completed the transaction later in 2021.

  Aftermath. The acquisition expanded Baxter into patient-care equipment, monitoring, connectivity, and digital hospital workflows.

  announced transaction value. $12.4 billion announced; approximately $12.5 billion at completion (2021)

  Source
• 2014Separate Baxalta from BaxterStrategy

  Baxter determined that its biopharmaceutical and medical-products businesses had distinct strategic and operating profiles.

  What changed. The company announced a separation, retaining the Baxter name for medical products and forming Baxalta as a standalone biopharmaceutical company.

  Aftermath. Baxalta began trading independently in 2015 and was later acquired by Shire.

  Source
• 2014Exit commercial vaccinesStrategy

  Baxter reassessed the role of vaccines within its reorganized portfolio.

  What changed. The company announced the sale of its commercial vaccine portfolio to Pfizer and explored options for its remaining vaccine research activities.

  Aftermath. Vaccines became less central to Baxter's post-separation medical-products strategy.

  Source
• 1985Merge with American Hospital SupplyM&A

  Baxter sought greater scale and a broader hospital-supply platform in the United States.

  What changed. Baxter merged with American Hospital Supply Corporation in a transaction described as creating a broad, integrated supplier for hospitals.

  Aftermath. The merger substantially expanded Baxter's product range, distribution reach, and organizational scale.

  Source

• 2024Hurricane Helene IV-fluid supply disruptionControversy

  Flooding at Baxter's Marion, North Carolina, plant interrupted production at a facility responsible for a large share of US IV-fluid supply, creating shortages and forcing hospitals to ration or conserve fluids.

  Source
• 2010Colleague infusion-pump recallControversy

  The FDA ordered a recall of Baxter's Colleague infusion pumps following numerous prior recalls and reported deaths associated with the devices.

  Source
• 2008Heparin contaminationControversy

  Heparin products linked to Baxter were associated by the FDA with deaths and severe allergic reactions. Investigators identified a contaminated raw material in the supply chain, after which Baxter initiated a recall and suspended production.

  Source
• 2001Althane dialysis disasterControversy

  More than 50 sudden deaths among kidney-failure patients in several countries were associated with Baxter's Althane hemodialysis equipment.

  Source
• 1996Settlement involving HIV-contaminated haemophilia productsControversy

  Baxter entered a major settlement concerning haemophilia patients, including Japanese patients, who contracted HIV after using contaminated blood-clotting concentrates.

  Source
• 1993Anti-boycott law violationControversy

  Baxter pleaded guilty to a felony related to US anti-boycott law after allegations concerning its international facilities and dealings connected with the Arab League boycott.

  Source
• 1975Hemofil withdrawal after hepatitis associationControversy

  Baxter and Travenol withdrew the clotting-factor product Hemofil after it was associated with an outbreak of hepatitis B.

  Source

• 2024Hurricane damage disrupts Baxter IV-fluid production

  Flooding from Hurricane Helene damaged Baxter's Marion, North Carolina, facility and contributed to widespread US intravenous-fluid shortages. The plant later resumed partial production.

  OtherRegulation
  Source
• 2024Baxter agrees to divest Vantive kidney-care business

  Baxter agreed to sell its kidney-care business, Vantive, to Carlyle in a transaction reported at approximately $3.8 billion.

  M&A
  Source
• 2023Baxter agrees to sell biopharma solutions business

  Baxter announced the sale of its biopharma solutions business to Warburg Pincus and Advent International for reported cash consideration of $4.25 billion.

  M&A
  Source
• 2021Baxter agrees to acquire Hillrom

  Baxter announced a multibillion-dollar acquisition of Hillrom, expanding its portfolio in patient care, connected technologies, and hospital equipment.

  M&A
  Source
• 2015Baxter completes the spin-off of Baxalta

  Baxalta began trading as an independent public company after being separated from Baxter.

  Other
  Source
• 2014Baxter announces separation of its biopharmaceutical and medical-products businesses

  Baxter announced a plan to create a standalone biopharmaceutical company, later named Baxalta, while retaining the Baxter name for the medical-products company.

  M&A
  Source

1. Baxter International
2. Baxter International corporate website